Matrix Metalloproteinase-13 - A Potential Biomarker for Detection and Prognostic Assessment of Patients with Esophageal Squamous Cell Carcinoma

Document Type: Systematic Review and Meta-analysis

Authors

1 Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

2 Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Radiotherapy and Oncology, Omid Hospital, Mashhad University of Medical Sciences,Mashhad, Iran

4 Department of Pathology, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Herbal biochemistry Department ,payamnoor university- Faculty of basic science- Biology Group, Mashhad, Iran.

Abstract

Background: Matric metalloproteinase (MMP) 13 gene expression is increased in esophageal squamous cell carcinomas (ESCCs) and associated with increasing tumor invasion, lymph node involvement and decreased survival rates. Levels of the circulating enzyme may be elevated and used as a marker of tumor progression. In this study, clinical application of MMP-13 serum levels was evaluated for early detection, prediction of prognosis and survival time of ESCC patients.
Materials and Methods: Serum levels of MMP13 were determined by ELISA in 66 ESCC patients prior of any treatment and 54 healthy controls for comparison with clinicopathological data through statistical analysis with Man Whitney U and Log-Rank tests. In addition, clinical value of MMP13 levels for diagnosis was evaluated by receiver operating characteristic (ROC) test.
Results: The serum level of MMP-13 in patients (>250 pg/ml) was significantly higher than in the control group (Conclusions: These findings indicate a potential clinical significance of serum MMP13 measurement for early detection and prognostic assessment in ESCC patients.

Keywords